RA-backed Pep­Gen sets terms for up­com­ing IPO; Sanofi com­mences dos­ing of De­nali can­di­date in ALS

Though the mar­ket has ex­pe­ri­enced a strong down­turn this year, a pre­car­i­ous few com­pa­nies are test­ing the IPO wa­ters. And Pep­Gen is the newest biotech to ap­proach Nas­daq.

The Phase I biotech said Mon­day that it plans to raise just over $100 mil­lion this week by of­fer­ing 7.2 mil­lion shares some­time this week. The price has not been set yet, but the cur­rent range would be be­tween $13 and 15 per share. At the mid­point of the range, it would give Pep­Gen a po­ten­tial mar­ket val­ue of around $300 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER